Burning Rock Biotech (NASDAQ:BNR) Shares Gap Up to $8.23

Burning Rock Biotech Limited (NASDAQ:BNRGet Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $8.23, but opened at $8.42. Burning Rock Biotech shares last traded at $8.00, with a volume of 1,662 shares traded.

Burning Rock Biotech Stock Up 3.4 %

The firm has a fifty day moving average price of $7.64 and a two-hundred day moving average price of $8.34.

Burning Rock Biotech (NASDAQ:BNRGet Free Report) last released its earnings results on Thursday, March 28th. The company reported ($2.20) earnings per share for the quarter. The business had revenue of $17.05 million for the quarter. Burning Rock Biotech had a negative return on equity of 71.77% and a negative net margin of 121.79%.

Institutional Investors Weigh In On Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. Lansdowne Partners UK LLP purchased a new position in Burning Rock Biotech Limited (NASDAQ:BNRFree Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 122,593 shares of the company’s stock, valued at approximately $119,000. Lansdowne Partners UK LLP owned approximately 0.12% of Burning Rock Biotech at the end of the most recent quarter. 30.03% of the stock is owned by hedge funds and other institutional investors.

About Burning Rock Biotech

(Get Free Report)

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Further Reading

Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.